Abstract
Emerging evidence indicates that metabolism not only is a source of energy and biomaterials for cell division but also acts as a driver of cancer cell plasticity and treatment resistance. This is because metabolic changes lead to remodeling of chromatin and reprogramming of gene expression patterns, furthering tumor cell phenotypic transitions. Therefore, the crosstalk between metabolism and epigenetics seems to hold immense potential for the discovery of novel therapeutic targets for various aggressive tumors. Here, we highlight recent discoveries supporting the concept that the cooperation between metabolism and epigenetics enables cancer to overcome mounting treatment-induced pressures. We discuss how specific metabolites contribute to cancer cell resilience and provide perspective on how simultaneously targeting these key forces could produce synergistic therapeutic effects to improve treatment outcomes.
Original language | English (US) |
---|---|
Pages (from-to) | 992-1008 |
Number of pages | 17 |
Journal | Trends in Cancer |
Volume | 10 |
Issue number | 11 |
DOIs | |
State | Published - Nov 2024 |
Funding
The Bonini laboratory is supported by grants from the National Institute of Environmental Health Sciences ( R01ES028149 , R01ES035723 , and R56ES033398 ), the National Cancer Institute ( R01CA216882 ), the National Heart, Lung, and Blood Institute ( R01HL163820 ), and the Lefkofsky Family Foundation Innovator Award, as well as philanthropic gifts from the H-Foundation and the Associate Board of the Lurie Cancer Center . The Bonini laboratory is supported by grants from the National Institute of Environmental Health Sciences (R01ES028149, R01ES035723, and R56ES033398), the National Cancer Institute (R01CA216882), the National Heart, Lung, and Blood Institute (R01HL163820), and the Lefkofsky Family Foundation Innovator Award, as well as philanthropic gifts from the H-Foundation and the Associate Board of the Lurie Cancer Center. The Gomes Laboratory is supported by the New Innovator Award from OD/NIH (DP2AG0776980), an American Cancer Society Research Scholar Award (RSG-22-164-01-MM), the National Institute of Aging (R21AG083720), the National Cancer Institute (R01CA279023), the Florida Health Department Bankhead-Coley Research Program (24B03), the Florida Breast Cancer Research Foundation, and the Phi Beta Psi Sorority. The authors declare no competing interests.
Keywords
- cancer metabolism
- epigenetics
- histones
- metabolites
- novel therapeutics
- post-translational modifications
ASJC Scopus subject areas
- Oncology
- Cancer Research